Could a simple anesthetic injection during surgery stop Triple-Negative breast cancer from coming back?

NCT ID NCT07458204

Not yet recruiting Disease control Sponsor: Institut Jean-Godinot Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether injecting the anesthetic levobupivacaine around the tumor and nearby nerves during breast cancer surgery can reduce the risk of the cancer returning. The study will include 760 women with triple-negative breast cancer who have had chemotherapy and are eligible for lumpectomy. Researchers will track recurrence and survival for two years after surgery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: levobupivacaine
What this could lead to: If it works, this could offer a simple, low-cost way to lower the risk of breast cancer returning after surgery.
What could go wrong: This is a phase 2 trial, so it's still early. The benefit seen in lab studies may not translate to people, and the drug's effect on recurrence is unproven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Recurrence triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TRIPLE NEGATIVE BREAST CANCER

Contacts and locations

Locations

Institut Godinot

Reims, Champagne-Ardenne, 51100, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.